" class="no-js "lang="en-US"> KaliVir Immunotherapeutics - Medtech Alert
Friday, August 15, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
KaliVir Immunotherapeutics | Pharmtech Focus

KaliVir Immunotherapeutics

About KaliVir Immunotherapeutics

KaliVir Immunotherapeutics

About

KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.

Related Story

Diseases

 ABL Partners With KaliVir Immunotherapeutics to Advance Development of Oncolytic Viruses | Pharmtech Focus

ABL Partners With KaliVir Immunotherapeutics to Advance Development of Oncolytic Viruses

July 12 2022

ABL, a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and […]

Diseases

 KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses | Pharmtech Focus

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses

May 24 2022

KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for […]